

REVIEW ARTICLE

C. Corey Hardin, M.D., Ph.D., *Editor*

Sepsis and Septic Shock

Nuala J. Meyer, M.D., and Hallie C. Prescott, M.D.

SEPSIS, A SYNDROME OF LIFE-THREATENING, ACUTE ORGAN DYSFUNCTION due to a dysregulated response to infection, is a major global health burden. Worldwide, an estimated 48.9 million cases of sepsis and 11 million related deaths occur annually.¹ In the United States, more than one third of in-hospital deaths are attributed to sepsis,² at costs exceeding \$38 billion in 2017, which makes sepsis both the most common cause of in-hospital death and the most expensive cause of hospitalization.³

Derived from the Greek word *sepo* (σηπω, translated as “I rot”), sepsis has been a leading cause of illness and death for millennia. According to the first modern definition, in 1992, sepsis was described as an overabundant inflammatory response to infection, recognized by the presence of the systemic inflammatory response syndrome (SIRS), which is defined as two or more abnormalities of temperature, heart rate, respiratory rate, or white-cell count.⁴ Sepsis was subsequently reconceptualized as life-threatening acute organ dysfunction due to a dysregulated host response to infection⁵ (Table 1). SIRS is no longer included in the definition of sepsis, since it may reflect a noninjurious host response, but recognition of the syndrome remains helpful for identifying infection.⁵

GLOBAL EPIDEMIOLOGY

Although sepsis is a global problem, the causes, incidence, and outcomes differ according to geographic region and age. Approximately 85% of cases and a disproportionate number of sepsis-related deaths occur in low- and middle-income countries,¹ with the highest age-standardized incidence in areas of greatest social vulnerability.¹ Sub-Saharan Africa is particularly affected, with 40% of cases worldwide.⁹ The considerable diversity of the pathogens involved, including pathogens that cause malaria, typhoid, and dengue, as well as human immunodeficiency virus (HIV) and its interaction with tuberculosis, also places a strain on sub-Saharan Africa and other low- and middle-income countries.^{1,9}

The most common sites of infection are pulmonary (accounting for 40 to 60% of cases), abdominal (15 to 30%), genitourinary (15 to 30%), bloodstream, and skin or soft tissue, with geographic variations.^{10,11} A pathogen is identified in approximately 60 to 70% of cases,¹⁰ and the percentage may increase as molecular testing for pathogen nucleic acids becomes more widespread.¹² The most common cause is gram-positive or gram-negative bacterial infection, followed by fungal or viral infection, although the incidence of viral sepsis can increase dramatically during pandemics.¹⁰ In the United States, candida species are the third most common pathogen type cultured from blood, after gram-positive and gram-negative bacteria.¹³

Risk factors for candidemia include prolonged critical illness, candida colonization, indwelling catheters, mucositis, advanced liver disease, receipt of total parenteral nutrition, and immunocompromise. Other common causes of fungal sepsis

From the Division of Pulmonary, Allergy, and Critical Care Medicine and the Center for Translational Lung Biology, Lung Biology Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia (N.J.M.); and the Department of Internal Medicine, University of Michigan, and VA Center for Clinical Management Research — both in Ann Arbor (H.C.P.). Dr. Meyer can be contacted at nuala.meyer@pennmedicine.upenn.edu or at 3600 Spruce St., 5037 Gates Bldg., Philadelphia, PA 19104.

This article was updated on December 5, 2024, at NEJM.org.

N Engl J Med 2024;391:2133-46.

DOI: 10.1056/NEJMra2403213

Copyright © 2024 Massachusetts Medical Society.

CME



KEY POINTS

SEPSIS AND SEPTIC SHOCK

- Sepsis is a syndrome of life-threatening acute organ dysfunction due to bacterial, fungal, parasitic, or viral infection.
- Factors that affect the risk of sepsis include age, immune status, pathogen virulence, and pathogen burden.
- Sepsis is associated with long-term complications among survivors.
- Biologic features of sepsis include dysregulated inflammation, immunosuppression, and vascular injury.
- Management of sepsis focuses on prompt infection control and hemodynamic resuscitation.
- Research is ongoing to determine whether and how to modulate the host immune response in order to improve outcomes.

are endemic fungi and *Pneumocystis jirovecii*. Risk factors for these opportunistic pathogens include immunosuppression, prolonged neutropenia, environmental exposures, and chronic lung disease. Sepsis-incident pathogens vary across the life span; both viral and diarrheal infections are more common in early childhood than later in life.¹⁴ In a global point-prevalence study involving pediatric intensive care units (ICUs) in 26 countries, 21% of sepsis cases were attributed to viral infection.¹⁵

Sepsis can occur in patients of any age, but the incidence varies markedly across the life span (Fig. 1). The incidence worldwide is highest among children younger than 5 years of age, with the nadir beginning in middle childhood and adolescence, and an exponential increase occurs starting at approximately 60 years of age.¹ Of 11 million deaths from sepsis in 2017, 26% occurred in children younger than 5 years of age.¹ Immaturity of the immune system explains some of the excess risk in the neonatal and early childhood period, since immunocompromise increases the risk of sepsis and enhances the pathogenicity of opportunistic organisms. The incidence of sepsis is also high among persons with chronic conditions that impair immune function, particularly patients with cancer, severe immunodeficiency, or kidney disease requiring hemodialysis. More than 20% of hospitalizations for sepsis among U.S. adults occur in patients with cancer,¹⁸ and the incidence of sepsis is increased by a factor of approximately 40 among patients receiving long-term hemodialysis.¹⁹

Evolving definitions and increasing recognition of sepsis have complicated the epidemiologic evaluation of the disorder.²⁰ The best available

global data indicate that the incidence of sepsis and associated mortality decreased by approximately 35% and 50%, respectively, from 1990 to 2017.¹ In the United States, hospitalizations for sepsis have increased over the past two decades, but this increase appears to be largely explained by greater recognition and diagnostic coding of sepsis.²¹ Studies based on clinical data suggest that the incidence and outcomes of sepsis are relatively stable over time in the United States.²²

BIOLOGIC FEATURES


IMMUNE DYSREGULATION

The well-regulated molecular response to infection has not been defined, but the prevailing view is that sepsis is a dysregulated immune response resulting in organ dysfunction. Progression to sepsis is influenced by pathogen virulence and abundance, as well as host features, including innate immune activation, relative immunosuppression, and maladaptive tolerance mechanisms.^{23,24} Many features of the expected inflammatory response — cytokine elaboration, excessive myelopoiesis, and generation of neutrophil–endothelial traps (NETs) — contribute to organ injury and perpetuate a disrupted immune homeostasis (Fig. 2).²⁵ (An expanded discussion of the biologic features of sepsis is provided in the Supplementary Appendix, available with the full text of this article at NEJM.org.) Furthermore, molecular profiling has revealed multiple patterns of response in gene expression,^{26,27} secreted proteins and metabolites,^{28,29} and leukocyte populations^{30,31} among patients. Specific high-risk molecular subphenotypes may have differential responses to certain therapies^{28,32} and are the focus

Table 1. Sepsis Definitions over Time.*

Consensus Definition	Year	Conceptualization of Sepsis	Identification of Sepsis	Identification of Severe Sepsis	Identification of Septic Shock
Sepsis-1 definition: Bone et al. ⁴	1992	Overwhelming inflammatory response to infection, as evidenced by SIRS	Infection plus two SIRS criteria as the result of infection: temperature $>38^{\circ}\text{C}$ or $<36^{\circ}\text{C}$, heart rate >90 beats/min, respiratory rate >20 breaths/min or PaCO_2 <32 mm Hg (4.3 kPa), or white-cell count $>12,000/\text{mm}^3$ or $<4000/\text{mm}^3$ or $>10\%$ immature bands	Sepsis associated with organ dysfunction, hypoperfusion, or hypotension	Sepsis-induced hypotension (SBP <90 mm Hg or reduced from baseline by ≥ 40 mm Hg in the absence of other causes of hypotension) despite adequate fluid resuscitation, along with perfusion abnormalities that may include lactic acidosis, oliguria, and acute alteration in mental status
Sepsis-2 definition: Levy et al. ⁶	2003	Overwhelming inflammatory response to infection, but the SIRS criterion is too narrow; the definition includes an expanded list of potential signs and symptoms of sepsis, reflecting bedside clinical experience	Infection plus two or more signs or symptoms of sepsis, including SIRS criteria, inflammatory markers (e.g., elevated C-reactive protein or procalcitonin), hemodynamic markers, organ-dysfunction markers, and tissue-perfusion markers	Sepsis complicated by organ dysfunction; unchanged from previous definition	Sepsis with acute circulatory failure characterized by persistent arterial hypotension (SBP <90 mm Hg, MAP <60 mm Hg, or SBP reduced from baseline by >40 mm Hg) despite adequate volume resuscitation and in the absence of other causes of shock
IPSCC definition: Goldstein et al. ⁷	2005	Overwhelming inflammatory response to infection, as evidenced by SIRS	Infection plus two SIRS criteria resulting from infection; at least one SIRS criterion must be abnormal temperature or white-cell count	Sepsis with cardiovascular organ dysfunction, ARDS, or dysfunction of two or more other organs	Sepsis with cardiovascular dysfunction despite fluid administration of 40 ml/kg in 1 hour, defined as hypotension ($<5\text{th}$ percentile or SBP <2 SD for age), need for vasoactive medication, or two or more of the following findings: unexplained metabolic acidosis, arterial lactate >2 times ULN, oliguria, prolonged capillary refill, or core-to-peripheral temperature gap
Sepsis-3 definition: Singer et al. ³	2016	Dysregulated host response to infection, resulting in acute organ dysfunction; SIRS may reflect a normal, noninjurious response to infection; although SIRS may be helpful for identifying infection, it is no longer included in the definition of sepsis	Infection plus life-threatening, infection-related acute organ dysfunction; life-threatening, acute organ dysfunction may be identified by an increase from baseline of ≥ 2 points in Sequential Organ Failure Assessment score	Severe sepsis is no longer identified as a separate entity; acute organ dysfunction is required for sepsis	Sepsis plus hypoperfusion, identified by hypotension requiring vasopressor support to maintain MAP ≥ 65 mm Hg and serum lactate level ≥ 2.0 mmol/liter after adequate fluid resuscitation
Phoenix definition: Schlapbach et al. ⁸	2024	Dysregulated host response to infection, resulting in acute organ dysfunction	Life-threatening organ dysfunction with suspected or confirmed infection, defined as a Phoenix Sepsis Score of ≥ 2 ; organ dysfunction may include respiratory, cardiovascular, coagulation, and neurologic systems	Severe sepsis is no longer identified as a separate entity; acute organ dysfunction is required for sepsis	Sepsis with cardiovascular organ dysfunction as indicated by severe hypotension for age; venous or arterial blood lactate level >5 mmol/liter (>45.05 mg/dl), or need for vasoactive medication

* The Sepsis-1, Sepsis-2, and Sepsis-3 definitions are for adult sepsis. The IPCC (International Pediatric Sepsis Consensus Conference) and Phoenix definitions are for pediatric sepsis. ARDS denotes acute respiratory distress syndrome, MAP mean arterial pressure, PaCO_2 partial pressure of carbon dioxide, SBP systolic blood pressure, SIRS systemic inflammatory response syndrome, and ULN upper limit of the normal range.



Along with excessive inflammation, patients with sepsis have suppression of innate and adaptive immune systems to varying degrees. Neutrophils, although more numerous, are relatively hypofunctional.³⁴ Peripheral-blood monocytes, which are major immune effector cells, have impaired cytokine secretion, a phenomenon termed endotoxin tolerance.³⁵ A specific subpopulation of monocytes, MS1 cells, is expanded during sepsis and augments immunosuppression.^{31,36} Absolute lymphopenia (absolute lymphocyte count, <1000 per high-power field) is common during sepsis, and persistent lymphopenia is associated with an increased risk of death.³⁷ The reduced lymphocyte count is due to lymphocyte apoptosis³⁸ and reduced lymphopoiesis,³⁰ and expanded regulatory T cells suppress proliferation and effector functions of many other immune cells.³⁹

Although concurrent hyperinflammation and immunosuppression during sepsis highlight the complexity of designing interventions to restore homeostasis, these seemingly opposing processes may be linked. Up-regulated immature neutrophils and MS1 cells stimulate ongoing myelopoiesis at the expense of typical hematopoiesis.^{30,36} Early responses to pathogens and damage signals trigger a shift in energy production from oxidative phosphorylation to aerobic glycolysis.⁴⁰ With repeated cytokine stimulation, monocytes obtained from patients with sepsis are “immune paralyzed” and have deficient glycolysis, oxidative phosphorylation, and beta-oxidation.⁴⁰ These metabolic deficiencies are largely reversed in survivors of sepsis,⁴⁰ which suggests that metabolic failure prompted by the very high energy needs for early host defense may underlie sepsis-induced immunosuppression. Lymphocytes obtained from patients with sepsis often express markers of immune exhaustion,^{41,42} which might be intrinsic to the specific T-cell population or reflect high T-cell activation.⁴³ Chronic stimulation of CD8+ T cells can produce exhausted, hypofunctional T cells, and studies have shown that dramatic T-cell activation in patients with sepsis is associated with an increased risk of death.^{44,45}

of clinical trials. Macrophage activation–like syndrome, a high-risk subtype, also has features of hyperinflammation and is under investigation in clinical trials.³³

DYSREGULATED VASCULATURE

The vasculature is a key site of injury in sepsis. The endothelium expresses abundant receptors for cytokines, chemokines, and damage signals




Figure 2. Pathobiology of Sepsis.

The pathobiology of sepsis is dominated by concurrent inflammation and hypofunctional immunity, with prominent microvascular injury. Activated neutrophils, macrophages, and cytotoxic T cells elaborate inflammatory and antimicrobial peptides and generate neutrophil–endothelial traps (NETs), which bind pathogens but further injure the endothelium. The bone marrow responds by generating more granulocytes — emergency myelopoiesis — at the expense of lymphopoiesis, and lymphocyte depletion is exacerbated by accelerated lymphocyte apoptosis. Neutrophils and macrophages have deficient cytokine production at the cellular level, and lymphocytes express markers for exhaustion. The vasculature is both permeable and activated, with a tendency toward increased thrombosis and reduced fibrinolysis. Host and pathogen factors dramatically influence the ways in which pathogens are introduced, detected, and responded to, as well as the resolution response. Given this variation in response, active research focuses on identifying features that best indicate a specific biologic dysregulation and that may thus predict a therapeutic response. The result of the pathobiologic process is organ injury and often multiorgan failure. ARDS denotes acute respiratory distress syndrome, and DAMP damage-associated molecular pattern.

and is thus primed to respond rapidly to pathogens and tissue injury. Although the vasculature is difficult to study — biopsies of blood vessels

are rare — multiple defects have been identified. Vessels shed their glycocalyx, a protective barrier that insulates the endothelium from circulating

blood cells and platelets, resulting in a predisposition to NET formation and leukocyte and platelet adhesion.⁴⁶ Activation of the complement system is critical for the host defense,⁴⁷ yet exuberant complement activation incites substantial tissue damage and microvascular thrombosis.⁴⁸ In the healthy state, the permeability of the endothelial barrier is adjusted to recruit leukocytes and nutrients to the site of infection, but regulation of endothelial permeability is often lost during sepsis. Clinically, this vascular dysregulation is manifested as hypotension, third spacing of fluid (loss of intravascular fluid into the interstitium), and in rare cases, frank disseminated intravascular coagulopathy. Treatments to enhance vascular barrier function have increased survival in animal models of sepsis,⁴⁹ but data from clinical trials of these treatments are lacking. Several treatments that target both inflammation and vascular activation, including activated protein C and statins, have shown promise; however, signals that the treatment response is heterogeneous across patient subgroups have often been observed.^{28,50}

CLINICAL PRESENTATION AND EVALUATION

The many combinations of infection site, pathogen, acute dysfunction of one or more organs, and baseline health status result in substantial heterogeneity of the clinical presentation. Patients often have general signs and symptoms of infection (e.g., fever or hypothermia and malaise) and symptoms that are specific to the site of infection (e.g., cough, dysuria, or erythema), as well as symptoms of acute organ dysfunction (e.g., confusion, oliguria, or dyspnea). However, timely recognition of sepsis can be challenging because the manifestations are heterogeneous, evolve over time, and may be subtle early in the disease process. Furthermore, common signs and symptoms are not specific to sepsis and may be masked by medications (e.g., beta-blockers or antipyretic agents).

Sepsis should be considered in all patients presenting with severe infection or acute organ dysfunction that is not clearly attributable to a noninfectious cause. For patients presenting with infection, clinicians should look for clinical and laboratory evidence of acute organ dysfunction. Altered mentation, hypotension, and tachypnea

are particularly suggestive of sepsis among patients with infection, although the absence of these signs does not rule out sepsis.⁵ Common laboratory findings that are characteristic of sepsis include leukocytosis or leukopenia, more than 10% immature granulocytes, hyperglycemia, and elevated levels of creatinine and lactate. Even in the absence of fever or localizing signs of infection, sepsis should be considered in patients with altered mentation, hypotension, dyspnea, and acute decompensation of chronic disease, such as diabetic ketoacidosis or decompensated cirrhosis.

The clinical evaluation focuses on confirming the site and cause of infection, as well as evaluating organ function and perfusion. Common testing to evaluate infection includes radiologic studies, microbial culture, antigen testing (e.g., tests for streptococcal and legionella antigen), and multiplex polymerase-chain-reaction pathogen-detection panels, depending on the suspected site. Three molecular diagnostic tests that determine the likelihood of sepsis are commercially available in the United States, but they have not yet been incorporated into routine practice. Lactate measurement is recommended in all patients to look for occult hypoperfusion.

MANAGEMENT

Management of sepsis focuses on infection control, restoration of perfusion, and organ support (Table S1 in the Supplementary Appendix). Restoration of immune homeostasis is also a goal but is the focus of ongoing research rather than a component of current clinical management. In this section, we focus on general treatment principles for infection control and resuscitation and highlight areas of ongoing research.

INFECTION CONTROL

Treatment of infection includes antimicrobial therapy, which is indicated for all bacterial and fungal infections and for many parasitic and viral infections causing sepsis, and procedural source control, which is indicated in some situations. The initial antimicrobial therapy is often empirical, since the causative pathogen is rarely known at the start of treatment. Prompt initiation of antimicrobial therapy is warranted because observational studies have indicated that mortality increases with delays in treatment administration,

particularly among patients with shock.⁵¹ The empirical antimicrobial regimen should cover the most likely pathogens on the basis of the suspected site (or sites) of infection, local epidemiologic factors, and risk factors for atypical or resistant organisms. Knowledge of the local epidemiologic profiles of pathogens, including antimicrobial resistance profiles, is helpful in selecting the initial therapy.

In addition, clinicians should consider each patient's risk profile, including pathogens and susceptibilities on previous cultures, conditions or treatments that may confer a predisposition to specific infections, a social history that may involve exposure to atypical pathogens, and signs, symptoms, and diagnostic data that may suggest the site or type of infection. Patients with previous antibiotic exposure and contact with the health care system have an increased risk of infection with resistant bacteria, so guidelines recommend broader initial coverage for such patients.^{52,53} Conversely, coverage should be withheld for pathogens that are unlikely to be the cause of infection in order to avoid adverse effects associated with antibiotic use. For example, the use of antianaerobic antibiotics depletes healthy enteric gut microbiota, is associated with adverse clinical outcomes,^{54,55} and can be avoided in many patients.⁵⁵

As further diagnostic information becomes available, antimicrobial therapy should be narrowed to cover the identified pathogen (or pathogens) and remove coverage of resistant organisms that have not been identified. The duration of antimicrobial therapy should be tailored to the site and type of infection and further guided by the clinical response, with shorter courses favored over longer courses of therapy.⁵³

Even with appropriate antimicrobial therapy, some infections require source control to improve the chance of a cure or minimize the risk of complications. Source control encompasses surgical and procedural interventions to remove the source of infection, reduce the pathogen burden, or correct anatomical derangements that impede normal clearance of infection. Common procedures for source control include removal of infected organs (e.g., appendectomy), removal of infected intravascular devices, relief of anatomical blockage proximal to the site of infection (e.g., biliary or genitourinary strictures), and drainage of abscesses or infected

fluid collections. Like antimicrobial therapy, source control is time-sensitive, and delays are associated with increased mortality, particularly among patients in shock.^{51,56} Since all interventions come with risks, consultation between critical care and procedural teams is important to determine the benefit and urgency of procedural source control.

RESTORATION OF ADEQUATE PERFUSION

For patients with hypotension or evidence of inadequate perfusion (e.g., elevated lactate levels), timely restoration of perfusion is critical and is the focus of several previous or ongoing clinical trials (Table 2). Intravenous crystalloid fluid is the first-line treatment to correct intravascular volume depletion and restore preload, although the approach to resuscitation has evolved over time (as discussed in the Supplementary Appendix).

Guidelines suggest 30 ml per kilogram of body weight as a reasonable initial fluid volume for most adult patients.⁵³ Fluid should be delivered in serial boluses (e.g., 250 to 1000 ml for adults), with close monitoring of the clinical response in patients who may have unacceptable side effects with a volume of 30 ml per kilogram. Prospective implementation of resuscitation bundles that involve a 30 ml per kilogram fluid bolus was reported to be associated with improved survival among patients with sepsis, including those with intermediate lactate values (2 to 4 mmol per liter), chronic kidney disease, or heart failure.⁷⁶

Both underresuscitation and overresuscitation are associated with harm, with observational studies showing a U-shaped relationship between fluid volume and outcomes.^{76,77} The harms of overresuscitation may be particularly prominent in settings with limited oxygen or ventilator availability.⁷⁸ However, results of trials that suggest harm from higher resuscitation volumes have generally used fluid volumes far exceeding 30 ml per kilogram.⁶⁴ For example, randomization to the resuscitation protocol in the Simplified Severe Sepsis Protocol 2 (SSSP-2) trial resulted in a median of 3.5 liters of fluid (≥ 70 ml per kilogram) being administered in the first 6 hours, as compared with 2.0 liters (≥ 50 ml per kilogram) in the usual care group, and was associated with increased mortality.⁶⁴ The use of balanced solutions, such as lactated Ringer's

Table 2. Landmark Sepsis Clinical Trials since 2015.*

Trial or Trials	Patients	Intervention and Control	Outcome	Interpretation and Lessons Learned
ARISE, ⁵⁷ ProCESS, ⁵⁸ and ProMISe ⁵⁹	ARISE: 1600 patients with septic shock at 51 sites in Australia and New Zealand ProCESS: 1341 patients with septic shock at 31 U.S. sites ProMISe: 1260 patients with septic shock at 56 U.K. sites	ARISE: EGDT vs. usual care ProCESS: EGDT vs. protocol-based "standard" therapy vs. usual care ProMISe: EGDT vs. usual care	ARISE: 90-day mortality, 18.6% vs. 18.8% (P=0.90) ProCESS: 60-day in-hospital mortality, 21.8% vs. 18.2% vs. 18.9% (P=0.83) ProMISe: 90-day mortality, 29.5% vs. 29.2% (P=0.90)	These trials showed that outcomes were similar with EGDT and usual care. Patients in these trials were less sick than those in the Rivers et al. trial (e.g., baseline ScvO_2 70% vs. 49%). ⁶⁰ However, there was no indication of benefit with EGDT across any subgroups examined in a meta-analysis of data from individual patients, including more severely ill patients. ⁶¹ Although these trials suggest that EGDT and usual care yield equivalent outcomes, EGDT is more labor-intensive, and standard care has evolved away from it.
ADRENAL and ⁶² APROCCHSS ⁶³	ADRENAL: 3800 patients with septic shock at 69 sites in Australia, United Kingdom, New Zealand, Saudi Arabia, and Denmark APROCCHSS: 1241 patients with multiorgan failure and septic shock at 34 sites in France	ADRENAL: hydrocortisone vs. placebo APROCCHSS: hydrocortisone plus fludrocortisone vs. placebo (and activated protein C vs. placebo)	ADRENAL: 90-day mortality, 27.9% vs. 28.8% (P=0.50) APROCCHSS: 90-day mortality, 43.0% vs. 49.1% (P=0.03)	Glucocorticoids were associated with reduced mortality in APROCCHSS but not in ADRENAL, although secondary outcomes in ADRENAL favored glucocorticoids. After these trials, guidelines were updated to include a weak recommendation to use glucocorticoids for persistent septic shock. ⁶³ However, the benefit varies among patients, so treatment decisions should be individualized.
SSSP-2 ⁶⁴	209 Patients with sepsis and hypotension at 1 site in Zambia	6-Hr sepsis bundle (administration of fluid boluses guided by JVP, vasopressors, and blood transfusion) vs. usual care	In-hospital mortality, 48.1% vs. 33.0% (P=0.03)	The sepsis bundle was associated with increased fluid delivery (median, 3.5 liters [≥ 70 ml/kg] vs. 2.0 liters [≥ 50 ml/kg] in the first 6 hr) and worse outcomes, underscoring the difficulty of translating sepsis management across settings and the need for further study of sepsis management in low- and middle-income countries.
PHANTAS ⁶⁵	2689 Patients with sepsis, identified in ambulance, at 34 sites in the Netherlands	Antibiotic administration before arrival at hospital vs. in hospital	28-Day mortality, 7.8% vs. 8.2%	In-ambulance antibiotic therapy yielded numerically but not significantly lower mortality. However, the difference of 0.4 percentage points is consistent with effect sizes in observational studies adjusted for less severely ill trial participants.

SMART ^{66,67} and BaSICS ^{68,69}	SMART: 15,802 patients (1641 with sepsis) at 1 U.S. site BaSICS: 10,520 patients (1987 with sepsis) at 75 sites in Brazil	SMART: balanced fluids vs. saline (0.9% sodium chloride) for IV fluid administration, with cluster randomization BaSICS: balanced fluids vs. saline (0.9% sodium chloride) for IV fluid administration	SMART: major adverse kidney event in overall trial population, 14.3% vs. 15.4% (P=0.04); 30-day in-hospital mortality among patients with sepsis, 26.3% vs. 31.2% (P=0.01) BaSICS: 90-day mortality, 26.4% vs. 27.2% (P=0.47); 92% probability of benefit among patients treated with balanced fluids before enrollment	These trials showed that resuscitation with balanced solutions is associated with better outcomes than resuscitation with normal saline, particularly among patients with sepsis and when used from the onset of resuscitation.
ANDROMEDA-SHOCK ^{70,71}	424 Patients with septic shock and lactate level ≥ 2.0 mmol/liter at 28 sites in Argentina, Chile, Colombia, Ecuador, and Uruguay	Capillary refill normalization vs. lactate normalization	28-Day mortality, 34.9% vs. 43.4% (P=0.06)	Capillary refill-guided resuscitation was associated with better outcomes than lactate normalization. In practice, both methods can be used.
65 trial ⁷²	2600 patients ≥ 65 yr of age with vasodilatory shock at 65 U.K. sites	Low MAP target (60–65 mm Hg) vs. usual care	Unadjusted 90-day mortality, 41.0% vs. 43.8% (P=0.15)	A lower MAP target was associated with numerically lower mortality, a finding that suggests that a vasopressor-sparing approach is safe in older adults.
FRESH ⁷³	124 Patients with septic shock at 13 U.S. and U.K. sites	Personalized resuscitation strategy based on change in stroke volume after passive leg raise vs. usual care	Renal-replacement therapy, 5.1% vs. 17.5% (P=0.04); invasive mechanical ventilation, 17.7% vs. 34.1% (P=0.04)	This trial showed the feasibility and potential benefit of a personalized resuscitation strategy. Larger trials powered for important clinical outcomes are needed.
CLASSIC ⁷⁴ and CLOVERS ⁷⁵	CLASSIC: 1554 patients with septic shock at 31 sites in Europe CLOVERS: 1563 patients with sepsis-induced hypotension	CLASSIC: fluid-restrictive resuscitation vs. usual care CLOVERS: fluid-restrictive vs. fluid-liberal resuscitation	CLASSIC: 90-day mortality, 42.3% vs. 42.1% (P=0.46) CLOVERS: 90-day mortality, 14.0% vs. 14.9%; estimated difference, -0.9 percentage points; 95% CI, -4.4 to 2.6 (P=0.61)	Fluid-restrictive and fluid-liberal resuscitation yielded similar outcomes in the overall trial populations, which suggests that more personalized approaches may be needed. Nearly all patients received ≥ 30 ml of fluids per kilogram, so these trials provide no data on the safety of limiting resuscitation to <30 ml/kg.

* ADRENAL denotes Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock, APROCCHS Activated Protein C and Corticosteroids for Human Septic Shock, ARISE Australasian Resuscitation in Sepsis Evaluation, BaSICS Balanced Solution versus Saline in Intensive Care Study, CLASSIC Conservative versus Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care, CLOVERS Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis, EGDT early goal-directed therapy, FRESH Fluid Response Evaluation in Sepsis Hypotension and Shock, IV intravenous, JVP jugular venous pressure, PHANTASI Prehospital Antibiotics Against Sepsis Trial, ProCESS Protocolized Care for Early Septic Shock, ProMISe Protocolised Management in Sepsis, ScvO₂ central venous oxygen saturation, SMART Isotonic Solutions and Major Adverse Renal Events Trial, and SSSP-2 Simplified Severe Sepsis Protocol 2.

solution, are preferred over 0.9% normal saline in patients with sepsis, on the basis of accruing evidence of reduced mortality,^{66,79} particularly when the solution is used for the entirety of resuscitation.⁶⁸

For patients with ongoing hypotension and volume depletion after initial resuscitation, “fluid-liberal” and “fluid-restrictive” approaches to ongoing resuscitation have yielded similar outcomes (Table 2).^{74,75} Personalized approaches to resuscitation that are based on dynamic physiological measures may be more effective than either a fluid-liberal or fluid-restrictive approach. Fluid responsiveness can be assessed on the basis of a change in stroke volume with a small fluid bolus (e.g., 4 ml per kilogram⁸⁰) or a passive leg-raise maneuver,⁸¹ which causes an “auto-bolus” by increasing blood return to the right ventricle. In a multicenter, randomized trial involving 124 patients with septic shock, patients who were assigned to receive fluid and vasopressor adjustment on the basis of a change in stroke volume (measured by a noninvasive cardiac output monitor) were less likely than patients assigned to usual care to require renal replacement therapy (5% vs. 17%, $P=0.04$) and invasive mechanical ventilation (18% vs. 34%, $P=0.04$), findings that support physiologically tailored resuscitation.⁷³ However, larger trials powered for important clinical outcomes are needed.

For patients with severe or persistent hypotension despite initial fluid administration, intravenous vasopressor therapy is warranted. Norepinephrine, the first-line vasopressor,⁵³ can be administered by means of central intravenous access or with the use of a high-quality peripheral intravenous catheter, with regular monitoring for extravasation.⁸² Guidelines recommend targeting an initial mean arterial pressure (MAP) of 65 mm Hg over higher MAP targets.⁵³ However, the 65 Trial suggests that a lower target of 60 to 65 mm Hg may be safe in some patients.⁷² In this trial, which involved 2600 patients with vasodilatory shock who were 65 years of age or older, randomization to permissive hypotension (MAP target, 60 to 65 mm Hg) resulted in less use of vasopressor therapy and lower adjusted mortality at 90 days than usual care (adjusted odds ratio, 0.82; 95% confidence interval [CI], 0.68 to 0.98).⁷²

Beyond MAP, the lactate level and capillary refill time provide additional information to guide

resuscitation and vasopressor dosing. A meta-analysis of four small trials showed that targeting resuscitation to a reduction in the serum lactate level, in addition to MAP targets, was associated with decreased mortality.⁸³ In the ANDROMEDA-SHOCK trial, 424 patients with septic shock were randomly assigned to undergo capillary refill–guided resuscitation or lactate-guided resuscitation. Patients for whom the assigned resuscitation approach failed despite a MAP of 65 mm Hg or higher received additional fluids, higher MAP targets, and ionotropes.⁷⁰ The patients assigned to undergo capillary refill–guided resuscitation had numerically lower mortality than patients assigned to lactate-guided resuscitation (34.9% vs. 43.4%; $P=0.06$), and a Bayesian reanalysis showed more than a 90% probability of lower mortality with capillary refill–guided resuscitation across multiple assumed probability distributions.⁷¹ For patients with a worsening clinical trajectory despite treatment with antimicrobial agents, fluids, and vasopressors, it is important to reconsider infection control and to determine whether broader antimicrobial agents, imaging studies to better define the site of infection, or source-control interventions are warranted.

For patients receiving ongoing vasopressor support, adjunctive “stress dose” glucocorticoids (hydrocortisone at a dose of 200 mg per day with or without fludrocortisone) should be considered. Meta-analyses have reached conflicting conclusions regarding a reduction in mortality but consistently show reductions in the duration of shock, mechanical ventilation, and ICU stay with adjunctive glucocorticoids.^{84,85} A recent observational target trial emulation showed that the addition of fludrocortisone to hydrocortisone was superior to hydrocortisone alone (adjusted difference in mortality, −3.7 percentage points; 95% CI, −4.2 to −3.1; $P<0.001$), without a signal for harm, and the combination was associated with lower all-cause mortality than with hydrocortisone alone in a Bayesian network meta-analysis.^{86,87} Although stress-dose glucocorticoids are beneficial in the average patient, the benefit varies among patients, so clinicians should weigh the severity of shock against the risk of glucocorticoid-associated adverse events when deciding whether to initiate and continue treatment with stress-dose glucocorticoids.⁸⁸ For patients with escalating norepinephrine requirements, the

addition of vasopressin — a noncatecholamine vasopressor — is recommended to spare catecholamine exposure. The dosage threshold for adding vasopressin is unclear and is currently being assessed in a multicenter trial (ClinicalTrials.gov number, NCT06217562).

RECOVERY AND LONG-TERM OUTCOMES

In addition to being an acutely life-threatening disorder, sepsis contributes to the development of other conditions, including cognitive impairment, functional impairment, and new or worsening chronic health conditions.⁸⁹ Among older adults, hospitalization with sepsis is associated with the development of new functional limitations (e.g., an inability to bathe or dress independently) and a large increase in the prevalence of moderate-to-severe cognitive impairment (6.1% before hospitalization vs. 16.7% after hospitalization).⁹⁰ Long-term complications are also common after pediatric sepsis. In a prospective cohort of 389 children with septic shock, 35% of surviving children had not regained their baseline health-related quality of life 1 year later.⁹¹

As a result of long-term health impairment, many patients who were employed before sepsis are unable to return to work. In a study involving 12,260 sepsis survivors in Norway who had worked before they were hospitalized for sepsis between 2010 and 2021, 40% had not returned to work at 6 months.⁹²

Beyond the health impairments that develop during hospitalization for sepsis, patients are at increased risk for further health deterioration, hospital readmission, and death in the months to years after the resolution of sepsis, outcomes that are not fully explained by age or preexisting conditions.^{89,93} A longitudinal study of sepsis survivors showed persistent activation of inflammatory and immunosuppressive markers in two thirds of the study participants, which was associated with increased all-cause mortality,⁹⁴ a finding that suggests that failure of the immune system to return to homeostasis may drive the risk of recurrent infection or progression of chronic conditions. Targeted therapies to enhance recovery from sepsis are lacking, but multicomponent interventions with primary care follow-up and proactive symptom assessment have been associated with improved survival.⁹⁵

AREAS OF CONTROVERSY OR UNCERTAINTY AND FUTURE RESEARCH

DIAGNOSIS

Sepsis is recognized as a syndrome of acute organ dysfunction due to a dysregulated host response to infection. However, we lack a precise definition of the dysregulated host response and a diagnostic test to confirm its presence. Moreover, we have limited ability to confirm or characterize infection in real time. Up to one third of patients who have been treated for presumed bacterial sepsis had a noninfectious illness in hindsight.⁹⁶ Even among patients with sepsis, the cause of the infection is not determined in up to one third of cases.¹⁰ Both protein-based and transcriptome-based tools have received U.S. and European approval for predicting the risk of sepsis, although whether their use changes outcomes is not yet known. As new tools are introduced,⁹⁷ their implementation in the clinical workflow and their effect on patient-centered outcomes should be tested.

SUBTYPES OF SEPSIS

The heterogeneity of sepsis has long been cited as an impediment to translation of preclinical studies and identification of targeted therapies.^{98,99} Over the past decade, several studies have identified and described new subtypes of pediatric and adult sepsis, including subtypes based on gene expression in blood leukocytes^{26,27}; clinical data, including pathogens^{100,101}; and plasma biomarkers.²⁸ Furthermore, in several post hoc applications of these classifications to clinical trial data, qualitative differences in the treatment response have been identified.^{32,100} Work is ongoing to translate these discoveries into improved management at the bedside.^{102,103}

HETEROGENEITY OF TREATMENT EFFECT

Clinical trials yield an average treatment effect, which may poorly reflect the expected treatment effect for an individual patient with sepsis, given the broad heterogeneity of the disorder. There is strong interest in predicting treatment effects in individual patients in order to improve bedside management. In a post hoc analysis of clinical trial data that used machine learning to estimate individual treatment effects, there was marked variation in the benefit of glucocorticoids for septic

shock.¹⁰⁴ Prospective trials are needed to test clinical decision-making support in order to guide management based on individual treatment effects.

TARGETED TREATMENT

The management of sepsis focuses on antimicrobial agents, source control, resuscitation, and support for organ failure. Targeted therapies to address specific forms of host dysregulation, including vascular permeability, are lacking. Several pharmacologic agents and devices are being studied, and efforts are under way to identify and characterize host response traits in a clinically actionable time frame.

SEPSIS IN LOW- AND MIDDLE-INCOME COUNTRIES

Although low- and middle-income countries have a disproportionately high share of sepsis cases and deaths,¹ most clinical trials have been performed in high-income countries. It is risky to extrapolate findings across settings, given the substantial geographic variation in pathogens, chronic conditions, and health care resources.⁷⁸ A major opportunity to improve global sepsis

outcomes is to enhance the health care infrastructure and research in areas that have the highest burden of sepsis.

CONCLUSIONS

Sepsis, defined as life-threatening acute organ dysfunction due to a dysregulated host response to infection, is a leading cause of illness and death worldwide. Tremendous variety in the infection site, causative pathogen, and the organs in which acute dysfunction occurs complicates both the recognition of sepsis and the identification of targeted therapies. Dysregulation of the host immune response is key to the pathogenesis of sepsis, but the current treatment approach focuses on the management of infection and restoration of perfusion. Research is ongoing to identify actionable subtypes of sepsis and develop targeted therapy for host dysregulation.

This article does not represent the views of the Department of Veterans Affairs or the U.S. government.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

REFERENCES

- Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. *Lancet* 2020;395:200-11.
- Rhee C, Jones TM, Hamad Y, et al. Prevalence, underlying causes, and preventability of sepsis-associated mortality in US acute care hospitals. *JAMA Netw Open* 2019;2(2):e187571.
- Liang L, Moore B, Soni A. National inpatient hospital costs: the most expensive conditions by payer, 2017. Statistical brief no. 261. Rockville, MD: Agency for Healthcare Research and Quality, 2020.
- Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Chest* 1992;101:1644-55.
- Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). *JAMA* 2016;315:801-10.
- Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. *Intensive Care Med* 2003;29:530-8.
- Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. *Pediatr Crit Care Med* 2005;6:2-8.
- Schlapbach LJ, Watson RS, Sorce LR, et al. International consensus criteria for pediatric sepsis and septic shock. *JAMA* 2024;331:665-74.
- Cummings MJ, Bakamutumaho B, Price A, et al. Multidimensional analysis of the host response reveals prognostic and pathogen-driven immune subtypes among adults with sepsis in Uganda. *Crit Care* 2022;26:36.
- Prescott HC. The epidemiology of sepsis. In: Wersinga WJ, Seymour CW, eds. *Handbook of sepsis*. Cham, Switzerland: Springer International Publishing, 2018:15-28.
- Weiss SL, Fitzgerald JC, Pappachan J, et al. Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. *Am J Respir Crit Care Med* 2015;191:1147-57.
- Kalantar KL, Neyton L, Abdelghany M, et al. Integrated host-microbe plasma metagenomics for sepsis diagnosis in a prospective cohort of critically ill adults. *Nat Microbiol* 2022;7:1805-16.
- Timsit J-F, Ruppé E, Barbier F, Tabah A, Bassetti M. Bloodstream infections in critically ill patients: an expert statement. *Intensive Care Med* 2020;46:266-84.
- Randolph AG, McCulloh RJ. Pediatric sepsis: important considerations for diagnosing and managing severe infections in infants, children, and adolescents. *Virulence* 2014;5:179-89.
- Fitzgerald JC, Basu RK, Akcan-Arikan A, et al. Acute kidney injury in pediatric severe sepsis: an independent risk factor for death and new disability. *Crit Care Med* 2016;44:2241-50.
- Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUPnet) (<http://hcupnet.ahrq.gov/>).
- Agency for Healthcare Research and Quality. Clinical classifications software refined (CCSR) for ICD-10-CM diagnoses. 2020 (https://www.hcup-us.ahrq.gov/toolssoftware/ccsr/ccs_refined.jsp).
- Hensley MK, Donnelly JP, Carlton EF, Prescott HC. Epidemiology and outcomes of cancer-related versus non-cancer-related sepsis hospitalizations. *Crit Care Med* 2019;47:1310-6.
- Sakhuja A, Nanchal RS, Gupta S, et al. Trends and outcomes of severe sepsis in patients on maintenance dialysis. *Am J Nephrol* 2016;43:97-103.
- World Health Organization. Global report on the epidemiology and burden of sepsis: current evidence, identifying gaps and future directions. September 9, 2020 (<https://www.who.int/publications/i/item/9789240010789>).
- Lindenauer PK, Lagu T, Shieh M-S, Pekow PS, Rothberg MB. Association of diagnostic coding with trends in hospitalizations and mortality of patients with pneumonia, 2003-2009. *JAMA* 2012;307:1405-13.

22. Rhee C, Dantes R, Epstein L, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. *JAMA* 2017;318:1241-9.
23. Shankar-Hari M, Calandra T, Soares MP, et al. Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies. *Lancet Respir Med* 2024; 12:323-36.
24. Wiersinga WJ, van der Poll T. Immunopathophysiology of human sepsis. *EBioMedicine* 2022;86:104363.
25. Medzhitov R. The spectrum of inflammatory responses. *Science* 2021;374:1070-5.
26. Sweeney TE, Azad TD, Donato M, et al. Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters. *Crit Care Med* 2018;46:915-25.
27. Cano-Gamez E, Burnham KL, Goh C, et al. An immune dysfunction score for stratification of patients with acute infection based on whole-blood gene expression. *Sci Transl Med* 2022;14(669): eabq4433.
28. Sinha P, Kerchberger VE, Willmore A, et al. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials. *Lancet Respir Med* 2023;11:965-74.
29. Rogers AJ, Leligodowicz A, Contrepois K, et al. Plasma metabolites in early sepsis identify distinct clusters defined by plasma lipids. *Crit Care Explor* 2021;3(8):e0478.
30. Kwok AJ, Allcock A, Ferreira RC, et al. Neutrophils and emergency granulopoiesis drive immune suppression and an extreme response endotype during sepsis. *Nat Immunol* 2023;24:767-79.
31. Reyes M, Filbin MR, Bhattacharyya RP, et al. An immune-cell signature of bacterial sepsis. *Nat Med* 2020;26:333-40.
32. Antcliffe DB, Burnham KL, Al-Beidh F, et al. Transcriptomic signatures in sepsis and a differential response to steroids: from the VANISH randomized trial. *Am J Respir Crit Care Med* 2019;199:980-6.
33. Kyriazopoulou E, Leventogiannis K, Norrby-Teglund A, et al. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. *BMC Med* 2017;15:172.
34. Demaret J, Venet F, Friggeri A, et al. Marked alterations of neutrophil functions during sepsis-induced immunosuppression. *J Leukoc Biol* 2015;98:1081-90.
35. Monneret G, Lepape A, Voirin N, et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. *Intensive Care Med* 2006;32:1175-83.
36. Reyes M, Filbin MR, Bhattacharyya RP, et al. Plasma from patients with bacterial sepsis or severe COVID-19 induces suppressive myeloid cell production from hematopoietic progenitors in vitro. *Sci Transl Med* 2021;13:eabe9599.
37. Drewry AM, Samra N, Skrupky LP, Fuller BM, Compton SM, Hotchkiss RS. Persistent lymphopenia after diagnosis of sepsis predicts mortality. *Shock* 2014;42: 383-91.
38. Shankar-Hari M, Fear D, Lavender P, et al. Activation-associated accelerated apoptosis of memory B cells in critically ill patients with sepsis. *Crit Care Med* 2017;45:875-82.
39. Souza-Fonseca-Guimaraes F, Parlato M, Fitting C, Cavaillon J-M, Adib-Conquy M. NK cell tolerance to TLR agonists mediated by regulatory T cells after polymicrobial sepsis. *J Immunol* 2012;188:5850-8.
40. Cheng S-C, Scicluna BP, Arts RJW, et al. Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. *Nat Immunol* 2016;17:406-13.
41. Boomer JS, Shuherrk-Shaffer J, Hotchkiss RS, Green JM. A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. *Crit Care* 2012;16(3):R112.
42. Wilson JK, Zhao Y, Singer M, Spencer J, Shankar-Hari M. Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis — pilot study. *Crit Care* 2018;22:95.
43. Baessler A, Vignali DAA. T cell exhaustion. *Annu Rev Immunol* 2024;42:179-206.
44. Lindell RB, Zhang D, Bush J, et al. Impaired lymphocyte responses in pediatric sepsis vary by pathogen type and are associated with features of immunometabolic dysregulation. *Shock* 2022;57:191-9.
45. Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. *Science* 2020; 369:eabc8511.
46. Uchimido R, Schmidt EP, Shapiro NI. The glycocalyx: a novel diagnostic and therapeutic target in sepsis. *Crit Care* 2019;23:16.
47. Bain W, Li H, van der Geest R, et al. Increased alternative complement pathway function and improved survival during critical illness. *Am J Respir Crit Care Med* 2020;202:230-40.
48. Mastellos DC, Hajishengallis G, Lambris JD. A guide to complement biology, pathology and therapeutic opportunity. *Nat Rev Immunol* 2024;24:118-41.
49. London NR, Zhu W, Bozza FA, et al. Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. *Sci Transl Med* 2010;2(23):23ra19.
50. McAuley DF, Laffey JG, O'Kane CM, et al. Simvastatin in the acute respiratory distress syndrome. *N Engl J Med* 2014; 371:1695-703.
51. Seymour CW, Gesten F, Prescott HC, et al. Time to treatment and mortality during mandated emergency care for sepsis. *N Engl J Med* 2017;376:2235-44.
52. Wu H, Harder C, Culley C. The 2016 clinical practice guidelines for management of hospital-acquired and ventilator-associated pneumonia. *Can J Hosp Pharm* 2017;70:251-2.
53. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. *Crit Care Med* 2021;49(11):e1063-e1143.
54. Chanderraj R, Baker JM, Kay SG, et al. In critically ill patients, anti-anaerobic antibiotics increase risk of adverse clinical outcomes. *Eur Respir J* 2023;61:2200910.
55. Chanderraj R, Admon AJ, He Y, et al. Mortality of patients with sepsis administered piperacillin-tazobactam vs cefepime. *JAMA Intern Med* 2024;184:769-77.
56. Rüdell H, Thomas-Rüdell DO, Reinhart K, et al. Adverse effects of delayed antimicrobial treatment and surgical source control in adults with sepsis: results of a planned secondary analysis of a cluster-randomized controlled trial. *Crit Care* 2022;26:51.
57. The ARISE Investigators, ANZICS Clinical Trials Group. Goal-directed resuscitation for patients with early septic shock. *N Engl J Med* 2014;371:1496-506.
58. The ProCESS Investigators. A randomized trial of protocol-based care for early septic shock. *N Engl J Med* 2014;370: 1683-93.
59. Mouncey PR, Osborn TM, Power GS, et al. Trial of early, goal-directed resuscitation for septic shock. *N Engl J Med* 2015;372:1301-11.
60. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med* 2001;345:1368-77.
61. The PRISM Investigators. Early, goal-directed therapy for septic shock — a patient-level meta-analysis. *N Engl J Med* 2017;376:2223-34.
62. Venkatesh B, Finfer S, Cohen J, et al. Adjunctive glucocorticoid therapy in patients with septic shock. *N Engl J Med* 2018;378:797-808.
63. Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. *N Engl J Med* 2018;378:809-18.
64. Andrews B, Semler MW, Muchemwa L, et al. Effect of an early resuscitation protocol on in-hospital mortality among adults with sepsis and hypotension: a randomized clinical trial. *JAMA* 2017;318: 1233-40.
65. Alam N, Oskam E, Stassen PM, et al. Prehospital antibiotics in the ambulance for sepsis: a multicentre, open label, randomised trial. *Lancet Respir Med* 2018;6: 40-50.
66. Brown RM, Wang L, Coston TD, et al. Balanced crystalloids versus saline in sepsis: a secondary analysis of the SMART clinical trial. *Am J Respir Crit Care Med* 2019;200:1487-95.
67. Semler MW, Self WH, Wanderer JP, et al. Balanced crystalloids versus saline in critically ill adults. *N Engl J Med* 2018; 378:829-39.

68. Zampieri FG, Machado FR, Biondi RS, et al. Association between type of fluid received prior to enrollment, type of admission, and effect of balanced crystalloid in critically ill adults: a secondary exploratory analysis of the BaSICS Clinical Trial. *Am J Respir Crit Care Med* 2022; 205:1419-28.
69. Zampieri FG, Machado FR, Biondi RS, et al. Effect of intravenous fluid treatment with a balanced solution vs 0.9% saline solution on mortality in critically ill patients: the BaSICS randomized clinical trial. *JAMA* 2021;326:1-12.
70. Hernández G, Ospina-Tascón GA, Damiani LP, et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. *JAMA* 2019;321:654-64.
71. Zampieri FG, Damiani LP, Bakker J, et al. Effects of a resuscitation strategy targeting peripheral perfusion status versus serum lactate levels among patients with septic shock: a Bayesian reanalysis of the ANDROMEDA-SHOCK Trial. *Am J Respir Crit Care Med* 2020;201:423-9.
72. Lamontagne F, Richards-Belle A, Thomas K, et al. Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension: a randomized clinical trial. *JAMA* 2020;323:938-49.
73. Douglas IS, Alapat PM, Corl KA, et al. Fluid response evaluation in sepsis hypotension and shock: a randomized clinical trial. *Chest* 2020;158:1431-45.
74. Meyhoff TS, Hjortrup PB, Wetterslev J, et al. Restriction of intravenous fluid in ICU patients with septic shock. *N Engl J Med* 2022;386:2459-70.
75. The National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network. Early restrictive or liberal fluid management for sepsis-induced hypotension. *N Engl J Med* 2023;388:499-510.
76. Liu VX, Morehouse JW, Marelich GP, et al. Multicenter implementation of a treatment bundle for patients with sepsis and intermediate lactate values. *Am J Respir Crit Care Med* 2016;193:1264-70.
77. Lat I, Coopersmith CM, De Backer D. The Surviving Sepsis Campaign: fluid resuscitation and vasopressor therapy research priorities in adult patients. *Crit Care Med* 2021;49:623-35.
78. Gendreau S, Frapard T, Carteaux G, et al. Geo-economic influence on the effect of fluid volume for sepsis resuscitation: a meta-analysis. *Am J Respir Crit Care Med* 2024;209:517-28.
79. Hammond NE, Zampieri FG, Di Tanna GL, et al. Balanced crystalloids versus saline in critically ill adults — a systematic review with meta-analysis. *NEJM Evid* 2022;1(2). DOI: 10.1056/EVIDoa2100010.
80. Aya HD, Rhodes A, Chis Ster I, Fletcher N, Grounds RM, Cecconi M. Hemodynamic effect of different doses of fluids for a fluid challenge: a quasi-randomized controlled study. *Crit Care Med* 2017; 45(2):e161-e168.
81. Bentzer P, Griesdale DE, Boyd J, MacLean K, Sirounis D, Ayas NT. Will this hemodynamically unstable patient respond to a bolus of intravenous fluids? *JAMA* 2016;316:1298-309.
82. Cardenas-Garcia J, Schaub KF, Belchikov YG, Narasimhan M, Koenig SJ, Mayo PH. Safety of peripheral intravenous administration of vasoactive medication. *J Hosp Med* 2015;10:581-5.
83. Gu W-J, Zhang Z, Bakker J. Early lactate clearance-guided therapy in patients with sepsis: a meta-analysis with trial sequential analysis of randomized controlled trials. *Intensive Care Med* 2015;41:1862-3.
84. Rygård SL, Butler E, Granholm A, et al. Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis. *Intensive Care Med* 2018;44: 1003-16.
85. Fang F, Zhang Y, Tang J, et al. Association of corticosteroid treatment with outcomes in adult patients with sepsis: a systematic review and meta-analysis. *JAMA Intern Med* 2019;179:213-23.
86. Bosch NA, Teja B, Law AC, Pang B, Jafarzadeh SR, Walkey AJ. Comparative effectiveness of fludrocortisone and hydrocortisone vs hydrocortisone alone among patients with septic shock. *JAMA Intern Med* 2023;183:451-9.
87. Teja B, Berube M, Pereira TV, et al. Effectiveness of fludrocortisone plus hydrocortisone versus hydrocortisone alone in septic shock: a systematic review and network meta-analysis of randomized controlled trials. *Am J Respir Crit Care Med* 2024;209:1219-28.
88. Prescott HC, Sussman JB. Smarter use of corticosteroids in treating patients with septic shock. *JAMA Netw Open* 2020;3(12):e2029323.
89. Prescott HC, Angus DC. Enhancing recovery from sepsis: a review. *JAMA* 2018;319:62-75.
90. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. *JAMA* 2010;304: 1787-94.
91. Zimmerman JJ, Banks R, Berg RA, et al. Trajectory of mortality and health-related quality of life morbidity following community-acquired pediatric septic shock. *Crit Care Med* 2020;48:329-37.
92. Skei NV, Moe K, Nilsen TIL, et al. Return to work after hospitalization for sepsis: a nationwide, registry-based cohort study. *Crit Care* 2023;27:443.
93. Prescott HC, Osterholzer JJ, Langa KM, Angus DC, Iwashyna TJ. Late mortality after sepsis: propensity matched cohort study. *BMJ* 2016;353:i2375.
94. Yende S, Kellum JA, Talisa VB, et al. Long-term host immune response trajectories among hospitalized patients with sepsis. *JAMA Netw Open* 2019;2(8):e198686.
95. Kowalkowski MA, Rios A, McSweeney J, et al. Effect of a transitional care intervention on rehospitalization and mortality after sepsis: a 12-month follow-up of a randomized clinical trial. *Am J Respir Crit Care Med* 2022;206:783-6.
96. Klein Klouwenberg PM, Cremer OL, van Vught LA, et al. Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study. *Crit Care* 2015;19:319.
97. Cajander S, Kox M, Scicluna BP, et al. Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine. *Lancet Respir Med* 2024;12:305-22.
98. Cohen J, Vincent J-L, Adhikari NK, et al. Sepsis: a roadmap for future research. *Lancet Infect Dis* 2015;15:581-614.
99. Prescott HC, Calfee CS, Thompson BT, Angus DC, Liu VX. Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. *Am J Respir Crit Care Med* 2016;194:147-55.
100. Seymour CW, Kennedy JN, Wang S, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. *JAMA* 2019;321: 2003-17.
101. Zhao H, Kennedy JN, Wang S, et al. Revising host phenotypes of sepsis using microbiology. *Front Med (Lausanne)* 2021;8:775511.
102. Gordon AC, Alipanah-Lechner N, Bos LD, et al. From ICU syndromes to ICU subphenotypes: consensus report and recommendations for developing precision medicine in the ICU. *Am J Respir Crit Care Med* 2024;210:155-66.
103. Maslove DM, Tang B, Shankar-Hari M, et al. Redefining critical illness. *Nat Med* 2022;28:1141-8.
104. Pirracchio R, Hubbard A, Sprung CL, Chevret S, Annane D. Assessment of machine learning to estimate the individual treatment effect of corticosteroids in septic shock. *JAMA Netw Open* 2020; 3(12):e2029050.

Copyright © 2024 Massachusetts Medical Society.